In vivo molecular targeted radiotherapy

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Therapy
• Oncology

Background:

• Unsealed radionuclides have been used therapeutically for over 50 years.
• Early applications included iodine-131 for thyroid conditions and phosphorus-32 for polycythemia vera.
• Recent advancements include bone-seeking agents and targeted radiopharmaceuticals.

Purpose of the Study:

• To review the history and development of unsealed radionuclide therapy.
• To explore the current applications and future potential of radiopharmaceutical agents.
• To highlight advancements in targeted therapies and novel radionuclide delivery systems.

Main Methods:

• Historical review of radiopharmaceutical therapeutic agents.
• Analysis of clinical applications and outcomes.
• Discussion of emerging technologies and future directions in radionuclide therapy.

Main Results:

• Established use of radionuclides like iodine-131, phosphorus-32, strontium-89, and yttrium-90.
• Development of targeted therapies including antibody conjugates for non-Hodgkin's lymphoma.
• Progress in bone pain palliation and somatostatin receptor targeting.

Conclusions:

• Radiopharmaceutical therapy has a long history with significant clinical benefits.
• Future therapies will likely involve targeted cytotoxic radionuclides and molecular constructs like aptamers.
• Advancements aim for greater efficacy, improved patient outcomes, and wider accessibility, including in remote areas.